Only 17.7% of pediatric anticancer drugs advance to phase 3 trials, and just 12% earn FDA approval within 10 years, compared to 38.7% for adult drugs. The pace of pediatric approvals has accelerated recently, but funding and market size constraints remain.
New AI-powered platforms enable same-day cancer treatment decisions and streamline clinical trial matching. University of Utah's μPharma chip predicts drug responses in under four hours, while City of Hope's HopeLLM system matches patients to trials across its national network.
New research examines both the long-term biological aging effects of childhood cancer treatments and proposes alternative treatment sequencing strategies to prevent tumor resistance and improve cure rates.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07594392 |
Clinical Assessment and Targeted Imaging to Characterize High-Risk Atherosclerotic Cardiovascular Disease of Survivors in SJLIFE |
NOT_YET_RECRUITING | |
| NCT07585136 |
Stem Cell Mobilization and Apheresis for Life-threatening Blood Disorders |
NOT_YET_RECRUITING | PHASE1 |
| NCT07531498 |
Muscle Aging Phenotypes in Childhood Cancer Survivors |
NOT_YET_RECRUITING | |
| NCT07516301 |
Feasibility of Incorporating a Standardized Substance Use Measure With Linked-Brief Intervention Into Routine Psychosocial Care of Adult Childhood Cancer Survivors |
NOT_YET_RECRUITING | NA |
| NCT07514819 |
Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma |
NOT_YET_RECRUITING | NA |
| NCT07502885 |
Deep Phenotyping Gait Deficits in Orthopedic Manifestations of Pediatric Cancer Patients |
RECRUITING | |
| NCT07456904 |
Outcomes of Health Care Transition for AYA With a Cancer Predisposition |
RECRUITING | |
| NCT07444216 |
A Longitudinal Photo-Narrative Exploration of Hope During Phase 1/2 Clinical Trials For Pediatric Cancer |
RECRUITING | |
| NCT07428993 |
Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma |
RECRUITING | PHASE2 |
| NCT07392216 |
Functional Ovarian Reserve in Sickle Cell Disease |
RECRUITING |
